Research programme: antibody therapeutics - Harbour Biomed

Drug Profile

Research programme: antibody therapeutics - Harbour Biomed

Alternative Names: HCAb antibody

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harbour BioMed
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Jun 2018 Harbour BioMed and WuXi Biologics agree to co-develop a HCAb antibody in China and World
  • 24 Jun 2018 Preclinical trials in Cancer in China (Parenteral) before June 2018
  • 27 Dec 2016 Harbour Antibodies' transgenic platforms are available for licensing as of 27 Dec 2016. http://www.harbourbiomed.com/partner.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top